Analysts are intrested in these 5 stocks: ( ($MRK) ), ( ($REGN) ), ( ($CLRB) ), ( ($HUMA) ) and ( ($FL) ). Here is a ...

Regeneron’s lead counsel was Jonathan D. Polkes of White & Case LLP.

MAIA Biotechnology, Inc. , a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that an abstract about the efficacy data from the Phase ...

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics ...

Progression-free survival data from more than 30 patients with first line pancreatic cancer in the ongoing Phase 2a trial of IMM-1-104 trial planned for announcement in 2Q’25 - - Reported positive ...

Applications are now open. The deadline to apply is May 16 at 4:29 p.m. The Starter Company Plus Grant supports eligible entrepreneurs looking to build their small businesses. Select entrepreneurs ...

The company’s Chief Scientific Officer, George D. Yancopoulos, M.D., Ph.D., expressed optimism about the potential of these treatments, including Libtayo, which is already a standard of care for ...

The company will highlight 18 presentations covering ... Key topics include results from the Phase 3 trial of Libtayo for high-risk cutaneous squamous cell carcinoma and data on linvoseltamab ...

“Our PD-1 inhibitor Libtayo is the standard of care in advanced cutaneous squamous cell carcinoma, and in clinical trials, our investigational BCMAxCD3 bispecific antibody linvoseltamab has ...

Below, you'll find some tips on a couple of different calculation methods to determine the number of shares of stock a company has. Image source: Getty Images. One simple calculation for the ...

The company also has an extremely full earlier ... Among oncology drugs, PD-1 antibody Libtayo is at the center, and is seeing solid growth (albeit from a smaller base) in niche indications ...